Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.

Kevin P NishimotoTaylor BarcaAruna AzameeraAmani MakkoukJason M RomeroLu BaiMary M BrodeyJackie Kennedy-WildeHui ShaoStephanie PapaioannouAmy DoanCynthia MasriNgoc T HoangHayden TessmanVidhya Dhevi RamanathanAna Giner-RubioFrank DelfinoKriti SharmaKevin BrayMatthew HoopesDaulet SatpayevRanjita SenguptaMarissa HerrmanStewart E AbbotBlake T AftabZili AnSwapna PanugantiSandra M Hayes

Published in: Clinical & translational immunology (2022)

Vδ1 γδ T cell, and a phase 1 study has been initiated in patients with B-cell malignancies (NCT04735471).

Keyphrases

immune response
stem cell transplantation
diffuse large b cell lymphoma
bone marrow
open label
cancer therapy
hematopoietic stem cell
cell therapy
high dose
nk cells
placebo controlled
clinical trial
low dose